Figure 5a & S4B clearly demonstrate that both normal and CML CD34+ cells are sensitive to DOR treatment, undergoing less cell divisions than NDC. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.